For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
How The No Surprises Act worsened the problem of surprise bills
Next week, Sen. Bill Cassidy (R-LA) will convene a roundtable to discuss adjustments to the 2020 No Surprises Act, which has come under…
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
News Release
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…
Search Posts
City Journal
Cuomo’s Vaccine Overreach
The New York governor’s incorrect claim that his state can review FDA vaccine approval will lead to more contagion and illness. New York…
Inside Sources
The Double Standard for Nicotine and Cannabis
The U.S. House of Representatives may soon vote on a historic measure to end federal prohibition on cannabis. Ironically, just as the public…
Study
The Double Standards of Cannabis and Nicotine
View Full Document as PDF Executive Summary The principal benefit of recreational cannabis, as the name implies, is recreation. Many who…
National Review
Cancel Culture Comes to Medicine
Cancel culture has come to medicine. Dr. Scott Atlas, who was chairman of neuroradiology at Stanford’s medical school until 2012 and more recently a senior…
News Release
Report: Politics, Not Science, Drives Double Standard on Cannabis, Nicotine Policies
As the House votes on a bill this month to end the federal prohibition on cannabis – once unthinkable – a new Competitive…
Blog
Trump’s Drug Price Controls are a Lousy Deal for Patients
Prescription drug prices are popular targets for lawmakers—especially in an election year. Still, it came as quite a surprise when President Trump issued an…